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1.1 Purpose of the study
Equine influenza is a highly contagious disease that has a significant impact on the
horse industry (Kernen, Frank, and Babish, 1985; Kita, 1993; Powell et al., 1995). The
influenza virus is transmitted by aerosol during transportation of horses, and under
conditions of overcrowding and stress. Infected horses develop respiratory symptoms that
can culminate in secondary bacterial pneumonia. The resulting exercise intolerance leads
to poor performance, and cancellation of race meetings, hence loss of revenue. The
influenza virus has a very high frequency of mutation (Parvin et al., 1986). It is the basis
of antigenic drift (Gething et al., 1980; Palese et al., 1980) whereby the structure of the
immunogenic, viral surface protein, the hemagglutinin (HA), changes frequently.
Therefore, animals that have been previously vaccinated may not be protected from
newly evolved strains.
Most of the current available vaccines rely on inactivated viruses. These vaccines
are poorly immunogenic. Furthermore, a different antigen presentation pathway for the
antigen is involved after intramuscular (i.m.) inoculation of inactivated vaccine when
compared to a natural infection, and a significantly lower immunity is elicited. Hence the
level of immunity is insufficient to protect horses from infection. One adverse
consequence is that a vaccinated animal can be infected sub-clinically, without any overt
symptoms. However, these animals can shed virus to infect others (Lai et al., 1994).
Furthermore, inactivated vaccines elicit only IgG responses, whereas IgA antibodies are
important in neutralizing the infecting virus at the mucosal sites (Clements and Murphy,
1986). The duration of immunity elicited by current inactivated vaccine is short. The
development and testing of such vaccines is also a time consuming process. Sometimes,
the demand for the vaccine cannot be met (Pound, 1980). Moreover, the strains that are
incorporated may no longer be relevant to those in circulation, due to the long lag time
for approval. Hence, there is an urgent need to develop a better alternative vaccine for
this disease.
1.2 Hypothesis
It has been established that i.m. vaccination of inactivated influenza virus produces
humoral immunity but no significant mucosal immunity (Clements and Murphy, 1986).
However, intranasal vaccination of inactivated vaccine has been shown to produce
significant elevation of serum IgA titers (Glueck, 2001). Similarly, live attenuated
vaccines have been found to elicit a longer duration of immunity than that obtained by
the use of an inactivated vaccine. Inactivated vaccines have the disadvantages of not
targeting the required kind of immune response. Live, attenuated virus elicits mucosal
immunity. However, in addition to the risk of reversion to the wild type, these vaccines
harbor a potential danger of genetic reassortment with other viruses, creating new
pathogenic strains.
A DNA vaccine is consisted of a plasmid encoding an immunogenic gene. The
plasmid is introduced into host cells. The encoded protein is transcribed and translated in
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the host cells. An immune response that resembles a natural infection IS elicited
(Gurunathan, Klinman, and Seder, 2000).
The HA protein is most important in eliciting protective immunity in influenza
infections (Virelizier, 1975), as anti-HA antibodies neutralize the virus and inhibit the
binding of the virus to host cell receptor. We hypothesized that by intranasal DNA
vaccination with a plasmid encoding the HA gene, a protective mucosal immunity will be
elicited. The HA protein would be synthesized de novo and will be expressed in its native
form in the host. The antigen presentation pathway of the HA resembles to that of a
natural infection. Stimulation of humoral immunity involving production of HA-specific
IgG, long-term anamnestic responses, and the highly desirable mucosal response
involving HA-specific IgA antibodies, will be elicited.
1.3 Overview of the research methodology
An expression vector pTOPO/V5/His was used to prepare the vaccine construct.
The HAl gene of equine-2 influenza virus, A/Eq/Kentucky/98, was inserted downstream
of the eukaryotic pCMV promoter. The plasmid DNA was amplified in Escherichia coli
cells.
To verify the expression of HA I, Madin-Darby canine kidney (MDCK) cells were
transfected with the DNA construct, using lipofectamine or by electroporation. The
cytosol and nuclear fractions were extracted, and subjected to a PCR to verify the
efficacy of transfection. Total cell lysates were subjected to Western blot hybridization,
usmg convalescent equme anti-KY/98 convalescent serum and goat anti-
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A/Eq/Miami/l/63 typing antiserum. To evaluate the efficacy of the D A vaccine, a
vaccine trial using Balb/c mice was perfonned. Groups of four mIce each were
vaccinated intranasally and challenged with homologous A/Eq/KY/98 equine influenza
virus. Anorexia is a major clinical symptom for mice infected with influenza virus.
Significant difference in weight loss between vaccinated and unvaccinated groups was
used to evaluate the degree of protection. Sera samples were also assayed for HA specific
IgG and IgA antibodies.
AMPLlFICATION AND PURIFICATION OF
DNA VACCINE
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The discovery of DNA vaccines has exciting implications in the prevention of
infectious diseases. This type of immunization is particularly useful for infections caused
by intracellular parasites, and for those diseases where a particular type of immune
response needs to be targeted. DNA vaccines have several advantages as a vaccine for
influenza. Updating the vaccine, due to antigenic drift, in will be much simplified: it will
involve only the cloning of the HA gene from the new strain, and the DNA vaccine
vector can be used and considered as the original licensed vaccine. In contrast,
manufacture of a conventional vaccine would involve adaptation of the strain to egg or
cell culture, safety and efficacy testing.
DNA vaccine elicits immunity that resembles that of a live attenuated vaccine,
and is stronger and longer lasting compared to the immunity elicited by an inactivated
vaccine (Clements and Murphy, 1986). Problems associated with live vaccines, for
example, reversion to virulence can be avoided. Furthermore, it has be shown that
intranasal inoculation of antigen elicits mucosal IgA responses (Glueck, 2001). Mucosal
immunity is highly desirable in the prevention of influenza infection. There have been no
major side effects associated with the use of DNA vaccines (Makela, 2000). Plasmid
DNA is a stable product that does not require sophisticated infrastructure for





2.1.1 Classification of influenza viruses:
The Orthomyxoviridae family contains two genera: influenza A and B viruses; and
influenza C virus. They are distinguishable based on the antigenic differences between
the major internal proteins M and RNP. Influenza A viruses are further classified into
subtypes based on the antigenicity of two surface viral proteins: the hemagglutinin (HA)
and the neuraminidase (NA). There are 15 different HA and 9 different NA subtypes of
influenza viruses identified so far. The nomenclature is according to the virus type, host,
and place of origin; isolate number, and year of isolation. The equine viruses are
influenza A viruses. The two major subtypes affecting horses are the H7N7 and H3N8.
They are designated as equine-l influenza and equine-2 influenza viruses, respectively.
Novel viruses of different subtypes can be generated when segments of the RNA
genome from two genetically distinct virus strains can be randomly reassorted, leading to




CLASSIFICATION OF INFLUENZA A VIRUSES
Hemagglutinin Humans Swine Horses Birds
HI PRl8/34 Sw/LAl15/30 None DkJAlb/35176
H2 Sing/1/57 None None DkJGer/1215173
H3 HK/1/68 SwITaiwan/70 EqIMiami/1/63 DkJCzJ56
H4 None None None DkJCZl56
H5 HK/156/97 None None Tern/S.A./61
H6 None None None TyIMass/3750/65
H7 None None Eq/Praguel1/56 FPYIDutchl27
H8 None None None Ty/Ont/6118/68
H9 HK/1/99 None None Ty/Wis/1/66
HIO None None None CkJGerIN149
HI1 None None None DkJEng/56
H12 None None None DkJAlb/60176
HI3 None None None Gull1MD1704/77
HI4 None None None DkJGurjev/263/82
HIS None None None DkJAustral1341 183
Neuraminidase Humans Swine Horses Birds
N1 PRl8/34 Sw/la/l5/30 None CkJScot/59
HK/156/97 SwITaiwan170 None None
N2 Sing/1/57 None None TyIMass/3750/65
HK/1/68 None None None
HK/1/99 None None None
N3 None None None Tern/S.A161
N4 None None None Ty/Ont/6118/68
N5 None None None ShlAustral/1 172
N6 None None None DkJCz/56
N7 None None Eq/Prague/I/56 FPYlDutchl27
N8 None None EqIMiami/l/63 Dk/Ukr/l/63
N9 None None None Dk/Mem/546174
Table 2-1: The two subtypes of equine viruses in circulation are the H3N8 and the H7N7. Most of the types
are found in avian species. Waterfowl serves as reservoir of the virus. Pigs have been implicated as mixing
vessels for reassortant viruses.
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2.1.2 Structure of the influenza virus
The influenza virus is highly pleomorphic, can be spherical or filamentous in
shape. The virus is enveloped and just beneath the membrane is the matrix protein (M),
which is the most abundant protein. The viral genome is comprised of eight segments of
negative-stranded RNA. Each segment encodes at least one protein. The two important
surface proteins are the hemagglutinin (HA) and the neuraminidase (NA). They project as
spikes from the viral surface. The function of HA is to initiate infection by binding to
sialic acid receptors on susceptible host cells. The role of NA is to prevent the
aggregation of viral particles, and in the release of progeny viruses. The nucleoprotein
(NP) packages the eight single stranded RNA segments. Viral encoded RNA-dependent
RNA Polymerases are PA, PB1 and PB2. Two nonstructural proteins comprise of NS1
and NS2. These proteins are associated with replication but are not found in progeny
virions (Flint S.l, 2000).
2.1.2.1 Hemagglutinin structure and importance:
Hemagglutinin is the most important immunogenic protein of the virus. For quine-
2 influenza virus, this viral RNA segment is consisted of 1762 nucleotides, and encodes a
565 amino-acid protein. The protein has two main domains, the HAl and HA2. The
monomer has a stalk that extends from the membrane and a globular head outside the
membrane. The stalk is composed of an alpha-helix and includes portions of the HAl and
HA2 segments. The HA1 and HA2 segments are held by a disulphide bond that is
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Australia and New Zealand are free of the disease so far (Mumford l.A, 1991; Wilson,
1993).
Three American and one Eurasian lineages of the H3N8 VIruS have been
identified based on changes in the HA sequence. Both American and Eurasian lineages
are present in Europe and the United Kingdom. Only one strain of the virus belonging to
the Eurasian lineage has been isolated in the Western Hemisphere (Lai et al., 2001). The
diverged evolution of equine-2 influenza virus complicates the choice of vaccine strains
in vaccine development. Outbreaks of equine influenza continue to occur, despite regular
and repeated vaccinations (Chambers.M., 1999)
2.1.4 Transmission
Transmission of the influenza ViruS is mainly by the aerosol route. Infected
animals exhale the virus during the initial stages of the disease, when they have the
characteristic hacking cough. The level of immunity ·of the contact animals will
determine the extent of transmission, and the intensity of symptoms. Previously
unexposed animals and unvaccinated animals exhibit the worst symptoms. Some
vaccinated animals, though protected from clinical disease, they can shed virus and infect
others (Lai et al., 1994; Mumford lA, 1991). Sub-clinical infection is the most
significant problem for the spread of the virus.
Transportation of horses is an important factor in dissemination of the disease
over distances, and sometimes across continents (Powell et al., 1995). The stress of
transportation, and the proximity of animals in close confinement, exacerbates the spread
of the virus. Outbreaks occur throughout the year, but are more frequent during the winter
10
months and during equine events, particularly during sales in the spring and in the fall.
Other stressful conditions like weaning, training or labor of drought horses can
exacerbate the condition. Although aerosol transmission is the primary means of spread,
contaminated water, personnel and transport vehicles have been implicated in disease
transmission (Guthrie, Stevens, and Bosman, 1999).
2.1.5 The disease and symptoms:
The influenza virus spreads rapidly and suddenly. High fever and a dry hacking
cough are the primary symptoms of influenza, followed by respiratory distress. In the
event of viremia, signs of myocarditis and congestive heart failure may occur. The virus
causes inflammation and edema of the respiratory epithelia. Secondary bacterial infection
may follow, and leads to bronchopneumonia. Animals that are forced to exercise despite
symptoms may experience exercise-induced pulmonary hemorrhages (Gross el al., 1998).
Though the mortality is not high, all susceptible animals are likely to be affected. The
disease can affect horses of all ages, but occurs most frequently in two to three year old
racehorses that have not been previously exposed or vaccinated (Wilson, 1993).
Influenza is a very important animal health and economic problem for the equine
industry (Mayr, 1987). Racehorses have to be withdrawn from training and exercise for
long periods oftime until their respiratory epithelium heals during course of recovery. An
animal with a severely damaged respiratory epithelium may have to be euthanized. In
case of an outbreak, entire race meetings may have to be cancelled, leading to loss of
revenue (Powell et al., 1995).
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2.2 Current vaccines:
The Office des Epizootics (DIE) recommendations state that both the Eurasian and
American lineages of equine2 influenza viruses should be incorporated in the vaccine,
while the use of equine-l influenza virus could be discontinued (Chambers.M., 1999).
However, currently commercial vaccines contain both equine-1 and equine-2 influenza
viruses. The herd immunity level influences the success of the vaccination program
(Peterhans, Zanoni, and Bertoni, 1999). Worldwide surveillance of the disease is
indispensable to effective control and vaccine manufacture.
In the production of vaccine, equine influenza viruses are cultivated in embryonated egg
or in cell culture. After chemical inactivation of the virus, adjuvants, like aluminum
hydroxide, oil and saponin, are added to enhance immunity. Adjuvant stimulates local
infiltration of lymphocytes to the site of injection, and slows the release of the antigen to
increase the duration of antigen stimulation. Side effects to the vaccine may include
localized swelling, pain or transient fever and rarely anaphylactic reactions. Egg proteins,
antigen and adjuvant in the product (Belgrave and Allpress, 1986) may induce these
adverse reactions.
Foals are vaccinated twice, with a gap of three to six weeks, followed by a booster
in the sixth month and annual vaccinations thereafter. Animals at high risk are vaccinated
every three to four months (Morley et al., 1999).
Current standard for vaccine potency is by the single radial immunodiffusion
(SRD) method (Wood et al., 1983). The DIE, however, recommends that animal
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challenge experiments should replace the serological criteria in licensing of new vaccines
(Chambers.M., 1999).
Improved vaccines for equine influenza include ISCOM (immune stimulating
complex) vaccines that include purified HA and NA antigens; adjuvanted with a
glycoside to form a complex lattice. These vaccines produce better and longer immune
responses, and were marketed in Scandinavia and Britain, but they are no longer
available (Sundquist, Lovgren, and Morein, 1988; Wilson, 1993). The use of cold
adapted, attenuated live virus delivered intranasally has been another practical and
successful approach to the problem. The virus replicates in the upper respiratory tract
only and does not infect the lower respiratory tract, where the temperature is higher
(Chambers et ai., 2001; Lunn et ai., 2001; Townsend et ai., 2001). However, the potential
danger of reversion to virulence remains. Reassortant virus vaccines are composed of
viruses with HA and NA proteins from human strains and nonstructural proteins from
avian strains were found to have low levels of pathogenicity, and induced protection
against the human strain. These approaches are of little practical use because live
vaccines can revert to virulence (Snyder et ai., 1986). Expression of surface proteins in
vaccinia was another approach for an alternative vaccine (De et ai., 1988), however, the
practicality of such vaccine is doubtful.
2.2.1 Difficulties in vaccine development:
The antigenic drift of influenza virus is the most important factor that hinders its
control. (Kawaoka, Bean, and Webster, 1989; Oxburgh et ai., 1994). The divergent
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evolution of the equine-2 influenza virus into three evolutionary lineages makes selection
of vaccine strains more difficult (Lai et al., 2001). Constant monitoring of the disease all
over the world, identification of emerging strains and constant evaluation of vaccine
strains in terms of protection afforded against circulating strains is indispensable.
Inadequacy of existing vaccines in terms of the type and duration of immunity elicited
(Nelson et al., 1998), lack of updated vaccines, and the spreading of the virus by
subclinically infected animals further complicate the issue of prevention of this disease.
2.3 Immune response to influenza:
2.3.1 General principles of immunity:
The immune response is a physiological reaction to infection, which helps to
contain and to eliminate the infectious agent during infection. It also possesses a memory
function. When the agent is encountered again, the response to it is accelerated, and more
specific. This phenomenon is called anamnesis. It is the basis for protection against
infectious diseases by vaccination.
Immunity can be divided broadly into the innate immunity and adaptive immunity.
Innate immunity is non-specific, but is the first line of defense and helps to limit the
infection. The various components of innate immunity include macrophages, natural
killer cells, interferon and the complement system. The microbe causes inflammation at
the site of entry leading to release of immune active mediators and influx of neutrophils
and lymphocytes. Phagocytic cells engulf the agent. Macrophages and dendritic cells act
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as antigen presenting cells that interact with the mechanisms of acquired immunity.
Increased levels of interferon are observed. The classical or alternate complement
pathways are activated, leading to the lysis ofthe infectious agent.
The adaptive immune response is mediated by T cells and B cells. These cell types
interact to produce a highly specific response. Antigen presentation to T cells requires
association with the MHC class I and II receptors. The two important classes of effector
T cells are CD4+ and CD8+ T cells. CD8+ T cells associate with MHC class i receptors
and have cytoiytic activity. CD4+ T cells are associated with MHC class II receptors.
After activation, they differentiate into Thl (Helper T cells type!) and Th2 (Helper T
cells type2). IL-12, IL-2, IFN-alpha and TNF-beta control the Thl response. This
response activates the CD8+ cytotoxic T cells. IL-l activates Th2 cells to produce IL-4,
IL-5, IL-6, IL-IO and IL-13, which in tum activate B cells to produce antibodies. B cells
produce antibodies of various classes including IgM, IgG, IgA, IgE and IgE. These
antibodies can directly neutralize the virus or help in innate immunity by triggering off
the complement pathway or antibody dependent cytotoxic cells (ADCC) (Kuby, 1992).
IgM appears early in the response. IgA is present at the mucosal surfaces. IgG appears
later in the response but is responsible for specific neutralization of the pathogen. IgE is












Fig 2-1: Immune response to influenza: Influenza virus gaining entry through the nasal mucosa, encounters
both innate immunity and acquired immunity of the host. Production of secretory IgA is an important
aspect of viral containment.
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2.3.2 Role of innate immunity in influenza:
Innate immunity plays a role in limiting the initial insult by influenza virus
infection. It limits dissemination of the virus and aids in the recovery. Natural killer cells
play an important role early during the viral infection (Stein-Streilein, Guffee, and Fan,
1988). Macrophages and natural killer cells in the lungs phagocitize the virus and act as
antigen presenting cells. They also produce alpha and beta interferon (Price, Gaszewska-
Mastarlarz, and Moskophidis, 2000). The complement system is activated through the
classical or alternate pathway. Activation of complement leads to the neutralization or
lysis of the virus (Lambre et ai., 1983).
2.3.3 Role of cell mediated immunity in influenza:
T lymphocytes play a crucial role in the recovery from influenza infection.
Macrophages and dendritic cells act as antigen presenting cells (APC). They interact with
two types of helper T cells (Th): Thl and Th2. On interaction with APC, Thl cells secret
IL-I2, IFN alpha and beta, and TNF beta. These cytokines activates CD8+ T cells
(cytotoxic T cells, CTL), and CD8+ cells recognize and cause the cytolysis of viral
infected cells. Interaction of the antigen presenting cells with Th2 cells leads to the
activation of CD4 positive T cells. CD4+ cells secrete IL-2, and other cytokines: ILA,
IL-5, IL6, IL-IO and 11.,-13. IL-2 signals the proliferation of other T cells, while IL-4, IL-
5 and IL-6 stimulate B cell differentiation and antibody secretion.
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MHC class II restricted CTL response in natural influenza infections is stronger
than that elicited with inactivated vaccines. Therefore, mice that were immunized with
live virus and later challenged with virulent virus were found to eliminate viruses in the
lung better than mice vaccinated with inactivated virus (Kris et ai., 1985; Wells et ai.,
1983). Cell-mediated immunity seems to confer some cross protection against
heterologous challenge. This was evident when the heterotypic protection was abolished
with the use of anti-thymocyte serum (Floc'h and Werner, 1978). However, CTLs can be
responsible for pathological lung tissue damage, possibly a result of their cytotoxic
activity (Yap, Braciale, and Ada, 1979). A systemic IgE response, also triggered by CTL,
contributes to the symptoms of the disease.
2.3.4 Role of humoral immunity in influenza:
Specific antibodies are produced by plasma cells. Plasma cells are activated B
cells. Antigen presenting cells stimulate Th2 cells to secrete cytokines that lead to the
proliferation and differentiation of plasma cells. Initially, antibodies of IgM isotype are
produced. On maturation, other isotypes are secreted, including IgG and IgA. IgA is a
major component of nasal secretion, while IgG is more abundant in the lower respiratory
tract (Gonchoroff et ai., 1982) and in serum. The duration of high antibody titer elicited
by natural infections can last for over a year. The antibody titer is short lived elicited by
inactivated vaccines (Glueck, 2001; Hannant, Mumford, and lessett, 1988). This is
attriibuted to a difference in the antigen presentation pathway. It has also been shown in
mice that serum antibodies play a role in virus clearance, act in conjunction with T
lymphocytes (Gerhard et ai., 1997). Antibodies also activate the classical complement
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pathway, and can result in complement mediated lysis of infected cells. Antibodies may
playa role in ADCC (antibody-dependent cytotoxicity) (Lambre et al., 1983); however,
the extent in virus clearance remains to be determined. HA specific antibodies appear to
be important (Virelizier, 1975), as a lack of it results in incomplete protection. Antibodies
to the matrix and nucleoprotein are also detected but they do not playa role in protection
(Virelizier, Oxford, and Schild, 1976). The specificity of the response depends entirely
upon the composition of the HA (Oxford et al., 1979).
2.3.5 Importance of mucosal immunity against influenza infection:
Mucosal-associated lymphoid tissues (MALT) are located at mucosal surfaces
like the gut, lungs, nose and others. T lymphocytes present in these areas secrete IL-4 in
response to infection and stimulate B cells to produce IgA and IgE. These cells can also
travel to other areas of the body (Davis, 2001).
Complete protection against natural influenza infections reqUIres local IgA
antibodies in the respiratory tract, as it is the site of initial virus attachment. Intranasal
administration of IgA in influenza-infected mice has been found to confer protection
(Renegar and Small, 1991b). When the IgA response was blocked, it was found that
previously infected mice could become susceptible to re-infection with the same virus
again (Renegar and Small, 1991a). Spread of the virus was arrested by formation of
complexes with secretory IgA in the nasal lamina-propria (Kaetzel et al., 1991).
Previously exposed animals are able to mount a quicker secretory IgA response (Hannant
et al., 1989). Secretory IgO responses have also been implicated in this response
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(Mbawuike et al., 1999). Therefore, design of an effective vaccine for influenza should
aim at stimulating both mucosal and systemic responses.
Intranasal delivery of live, inactivated, subunit and DNA influenza vaccines by
several means like ISCOMS, virosomes, proteosomes, liposomes and polymers have
demonstrated the ability to induce protective mucosal immunity (Gluck, 1999; Gruber et
al., 1993; Hu, Lovgren-Bengtsson, and Morein, 2001; Kadowaki et at., 2000; Klavinskis
et al., 1997; Levi et al., 1995; Payne et aI., 1995; Singh, Briones, and O'Hagan, 2001).
The advantages of this method of delivery over other methods are that the vaccine is easy
to deliver and does not require needles and syringes that are potential sources of disease
transmission. Further, the nose is easily accessible, highly vascular, and has a large
surface for absorption. This route elicits both systemic and mucosal responses. Distant
mucosal cells can also be involved in the response due to dissemination of effector cells
(Davis, 2001). It is a very cost-effective delivery system (Luce et al., 2001). Furthermore,
intranasal delivery of an inactivated influenza vaccine has been shown to induce B cell
dependent heterotypic cross-protection (Tumpey et at., 2001).
2.4 DNA vaccines:
When DNA expreSSiOn vectors encoding genes for chloramphenicol acetyl
transferase and luciferase were injected into muscle tissue, it was found that the encoded
proteins were expressed by the transfected cells (Wolff et al., 1990). Further study proved
that plasmid DNA persisted in the cells for at least nineteen months but did not replicate
in them. The plasmid DNA remains extra-chromosomal (Wolff et al., 1992) though
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inside the nucleus. This discovery had important implications in the field of vaccinology.
DNA vaccine studies with plasmid DNA encoding immunogenic genes of various
pathogens using several routes and means of delivery and in different animal models
have been carried out since then (Klavinskis et al., 1997; Montgomery et al., 1993; Raz
et al., 1994; Sasaki et al., 1998). It is found that this approach is particularly useful in
eliminating infections by intracellular parasites, because both cell-mediated and humoral
immunity are stimulated. DNA vaccines also have applications in cancer and allergy
therapy (Cohen, 2000; Sato and Kasukawa, 2000). Therefore, DNA immunization can
offset several of the problems associated with producing an effective vaccine for
influenza.
2.4.1 Basic requirements of a DNA vaccine:
The plasmid DNA vaccine should contain a cloning site where the gene of interest
can be incorporated. It should also contain an antibiotic resistance gene to enable
selection. A bacterial origin of replication is required for replication in bacteria. Since the
vaccine is used in mammals, a powerful promoter for enhanced expression in mammalian
cells is useful (Robinson, Hunt, and Webster, 1993). Viral promoters from
cytomegalovirus and SV40 virus are nonnally incorporated. Since plasmids are of
bacterial origin, certain palindrome motifs of unmethylated cytidine-phosphate-
guanosine dinucleotides (CpO) are known to stimulate natural killer cells to secrete
interferon gamma and other cytokines that enhance the B cell immune response (Klinman
et al., 1996; Krieg et al., 1995). Such CpO motifs are incorporated in most DNA vaccine
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vectors. Polyadenylation sequences derived from SV40 virus or from bovine growth
hormone are incorporated to stabilize mRNA transcripts.
2.4.2 Route of administration:
Transfection of mammalian cells with plasmid DNA encoding viral antigens has
been known to lead to antigen expression in several cell types and stimulation of various
antigen presentation pathways. Detectable levels of antigen or plasmid are not required
for persistence of the response (Akbari et al., 1999; Wolff et al., 1992). The reason for
this anomaly may be persistence of antigen in follicular dendritic cells or stimulation of
an antigen independent response (Gurunathan, Klinman, and Seder, 2000).
In DNA vaccination, the route of administration has a direct correlation with the
type of immune reaction that is elicited and the types of cells that are transfected. Upon
gene gun vaccination, dendritic cells are directly transfected and they express the protein
and present it to T cells (Akbari et al., 1999; Porgador et al., 1998). Intramuscular
injections of plasmid DNA transfect muscle cells (Ulmer et al., 1996). However, this
route generates other T cell responses by migration of the plasmid DNA from the site of
injection to lymph nodes where dendritic cells are transfected (Akbari et al., 1999; Wolff
et al., 1990). Intradermal vaccinations lead to transfection of keratinocytes and
Langerhans cells (Hengge et al., 1998). The keratinocytes remain at the site of
vaccination to stimulate a local response. Therefore, cross priming of cells is an
important mechanism by which a response is elicited to DNA vaccines. Antigens
expressed by transfected somatic cells may be taken up other professional antigen
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presenting cells to stimulate T cell responses (Ulmer J.B, 1998). Mucosal administration
of DNA by various routes like intranasally (Wong et al., 200 I), intra-tracheally (Fynan et
al., 1993) and in the genital tract (Livingston et al., 1998), by aerosols (Stribling et al.,
1992) combined with adjuvant like cholera toxin (Ban et al., 1997), liposomes
(Klavinskis et al., 1997), cytokine genes (Larsen et al., 1998) and saponin (Sasaki et al.,














Figure 2-2: The mechanism of action of DNA vaccines: Fusion of the liposome with the cell membrane
releases plasmid DNA into the cytosol. The antigen is transcribed, translated, secreted, and processed by
antigen presenting cells. Cytosolic protein is engulfed by lysosomes, processed and presented in association
with MHC class I molecules.
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2.4.3 Immune responses to DNA vaccination:
2.4.3.1 Effects on cytotoxic T lymphocytes:
The major difference between immunity produced by a live viral infection and an
inactivated vaccine is that the strength of the response is greater and the duration of
immunity produced is much longer in a live viral infection. This can be attributed to the
stimulation of CD8+ CTL (Kris el al., 1985). The most important advantage of a DNA
vaccine lies in the fact that it functions in a manner similar to that of an attenuated, live,
vaccine. The antigen is synthesized endogenously. Therefore, a strong CTL response,
which is specific and has a strong memory, is generated (Chen, Webster, and Woodland,
1998; Fu el al., 1997).
2.4.3.2 Effects on Helper T cells:
Thl and Th2 cells are functionally different products of the activation of CD4+ T
cells. They are differentiated depending on the cytokines they secrete (Mosmann and
Coffman, 1989). Th1 and Th2 responses are mutually suppressive (Mosmann, 1991;
Parish, 1972). Intracellular parasites and viral infections require a Th1 response while
extracellular; bacterial infections require a Th2 response.
A major advantage of the DNA vaccine is that the response can be modulated to
suit the type of disease that it is targeted. This can be done by the incorporation of desired
cytokine genes in the vaccine (Larsen el al., 1998; Min et al., 2001). Alternatively, by
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including a secretory signal in the encoded protein can bias the response towards a Th2
response, while a protein localized in the cytoplasm will stimulate a Th 1 response
(Haddad et ai., 1997). Gene gun inoculations favor Th2 types of responses, and
intramuscular injections stimulate a Thl type response (Pertmer, Roberts, and Haynes,
1996). Intranasal administration favors a mucosal Th2, IgA response (Durrani et ai.,
1998; Lundholm et ai., 1999). Due to the dichotomy of the Thl and Th2 responses, DNA
vaccination can be used to suppress one response by stimulation of the other. This
approach is particularly useful in treatment of allergies where a Th2 response causes
secretion of IgE (Raz et ai., 1996).
2.4.3.3 Effects on humoral immunity:
While innate and CTL responses help to contain the disease, humoral responses are
indispensable in viral clearance, resolution of the disease and generating specific memory
responses. DNA vaccines produce antigen specific responses and the classes of
antibodies detected include IgG, IgM and IgA (Deck et ai., 1997). The dose, route and
interval between vaccinations influence the magnitude of the response. In mice, about 10
-100 ug of plasmid DNA delivered intramuscularly, and 0.1 - 1.0 ug delivered using a
gene gun have been shown to elicit an immune response (Fynan et ai., 1993). Booster
immunizations with a four-week interval have been shown to increase serological
responses (Deck el ai., 1997), (Fuller et ai., 1997). The results vary with the model used
and the organism involved.
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Peak antibody responses occur between 4 - 12 weeks after DNA immunization.
Persistence of antibody levels for up to 1.5 years after vaccination (Deck et al., 1997) has
been recorded. Although antibody titers generated by a live vaccine have been shown
higher than that generated by a DNA vaccine, this does not affect the protection elicited
by DNA vaccines (Deck et al., 1997). Since the protein will be produced in its native
form, the type of antibody response generated will resemble that of a live viral infection
(Peet et al., 1997). Gene-gun vaccination of secreted antigen induces IgG response, and
the response resembles a natural infection (Pertmer, Roberts, and Haynes, 1996).
Intranasal DNA vaccinations elicit a mucosal IgA response (Sasaki et al., 1998).
2.4.4 Advantages of DNA vaccination:
In summary, DNA vaccination is one the most versatile techniques that holds great
promise for the future in the control of infectious diseases. Several immunogenic antigens
can be incorporated in the same DNA construct to form a multi-gene vaccine. For
influenza, currently prevalent strains can be incorporated in a timely fashion to meet
market demands. Both cellular and humoral immunity are elicited. The protection elicited
by these vaccines is comparable to live attenuated vaccines. The immune response can be
modulated by several means to suit a particular disease. No specialized infrastructure is
required for the production of the vaccine. Plasmid DNA forms a stable product and does
not require cold chain preservation. Improved drug delivery systems make it easy to
administer and cost-effective under field conditions.
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Some concerns about use of these vaccines include the possibility that the DNA
may integrate into the host chromosome. The host's normal cytokine responses may be
irreversibly altered and can lead to autoimmunity. Immune tolerance, rather than
immunity might be induced (Gurunathan, Klinman, andSeder, 2000). While extensive
studies have not been conducted on these aspects, there have been no recorded adverse
effects (Makela, 2000), except for an incidence of malarial DNA vaccine inducing
immune tolerance rather than immunity in newborn mice (lchino et ai., 1999).
Significantly, the plasmid DNA does not integrate into the host chromosomes (Wolff et
al., 1992).
2.4.5 DNA vaccines and equine influenza:
The influenza virus has been a model organism in the study of DNA vaccines. In
1993 it was found that a HA expressing plasmid could confer protection against
influenza (Robinson, Hunt, and Webster, 1993). Use of the NA gene conferred
heterologous protection (Ulmer et al., 1993). The immune responses involved were later
characterized. Both cell mediated and humoral responses were found to be involved
(Yankauckas et al., 1993). Inclusion of both the HA and NA genes elicited both
homologous and heterologous protection (Donnelly et al., 1995; Montgomery et al.,
1993). Various routes of inoculation, including the gene-gun, mucosal and parenteral
were compared (Fynan et al., 1993). Various animal models, including ferrets (Donnelly
et al., 1997), baboons (Bot et al., 1999) and mice (Justewicz and Webster, 1996) were
used. The role of cytotoxic T cells (Fu et al., 1997; Iwasaki et al., 1997) and effects of
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cytokine encoding genes (Larsen ef al., 1998; Lee el al., 1999) in DNA vaccination
against influenza were studied.
Similar studies on DNA vaccmes for equme influenza were also carried out.
Particle mediated delivery of HA encoding plasmid at skin and mucosal sites (tongue,
conjunctiva and third eyelid) in ponies was found to stimulate IgG responses but a poor
IgA response (Lunn et al., 1999). However, the intranasal route was not used in this
study. Immunization with a human IL-6 encoding gene along with the HA gene by gene-
gun delivery was found to enhance viral clearance responses (Larsen et aZ., 1998). The
use of a gene-gun is impractical under field conditions, and the equine IL-6 needs to be
characterized. The use of a recombinant A/Eq/KYIl/81 HA protein was expressed in a
baculovirus system. Intranasal inoculation of this protein was compared with gene-gun
vaccination of a HA encoding DNA vaccine. The DNA vaccine induced complete
protection (Olsen ef aZ., 1997). Intranasal, liposome-mediated delivery of A/Eq/Pr/l/56
HA has been found to confer protection, and elicited both serum IgG and IgA antibody
production (Wong et aZ., 2001). The H3N8 subtypes of the virus used in this study are
more relevant, as candidate vaccine strains since the H7N7 subtypes have not been
recently recorded. This study is to test the use of only the HAl to elicit protection, in




3.1 Materials and methods:
The HAl gene of equine-2 influenza virus, A/Eq/KY/98, was extracted from an
allantoic fluid culture of the virus. The gene was cloned into a mammalian expression
vector pTOPO 3.1 (Invitrogen, Carlsbad, CA). One clone was prepared without a 3' stop
codon, and it's ORF was in frame with the C terminal His tag (designated pHAl). The
second clone contains a 3' stop codon (designated pHA2). Competent E. coli cells were
transformed with the plasmid. Clones were selected for the presence of ampicillin
resistance. These clones were constructed and characterized by Lai et al (unpublished
results). As described previously, these clones were further characterized in vitro and in










200 VTVST IIIIINIGSRPWVRGQSGRISIYWTIVKP SNGNL
250 VAPRGYFKLKTGKSSVMRSDAlIlIlIsECITPNGSIPNDKPFQNVNKVT
300 YGKCPKYIRQNTLKLATGMRNIPEKQIR
Fig 3-1: Map of the DNA vaccine construct: showing the pCMV promoter (5' of the HA gene), the His tag,
and ampicillin resistance gene. The amino acid sequence the HA I gene, including the signal peptide
(shaded yeIlow), and the antigenic sites A, B, C and D (shaded Blue, Green, Pink and Red, respectively)
are shown in the table below. Adapted from (Lai et at., 2001)
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3.1.1 Restriction digest:
Plasmid DNA was extracted from the individual clones and subjected to restriction
digestion for verification of the presence of the insert. Five micro liters of the extracted
DNA were added to 0.5 ul of Hind III, 0.5ul of EcoRV, 1.0 ul of reaction buffer and 3.0
ul of distilled water to make a total reaction volume of 10.0 ul. The mixture was
incubated for two hours at 37DC.
To visualize the DNA, 5.0 ul of the digested DNA was mixed with 5.0 ul of
tracking dye (.25%(w/v) bromophenol blue, 20% glycerol, 0.1 M EDTA, pH 8) and
loaded on a 1.5% (WIV) agarose gel. The gel was run for 20 minutes at 100 V in TBE
buffer (89.0 mM boric acid, 89.0 mM Tris, 2.0 mM EDTA, pH 8). Ethidium bromide was
added at 1.0 ug/ml concentration to stain the gel for 10 minutes. The gel was visualized
under ultraviolet light, and the presence of the expected 1.0 Kb fragment was confirmed.
3.1.2 peR for verification of the orientation of the insert:
Aliquots of lyophilized 2X MasterMlx PCR buffer (Promega, Madison, Wisconsin) were
reconstituted to a volume of 17.0 ul with nuclease free water. The mix contains 50.0 mM
Tris HCI (pH 9.0) and 3.0 mM MgCI2, 400.0 uM each of dNTPs and 50.0 units/ml of
Taq DNA polymerase in reaction buffer (pH 8.5). 1.0 ul of extracted plasmid DNA and
1.0 ul of T7 forward primer and 1.0 ul of reverse primer EH3-415+ were added to the
tube to make up a total volume of 20.0 ul. The cycle parameters included denaturing at
95DC for 30 seconds, annealing at 42 DC for 30 seconds, extension at 72 DC for one minute
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for a total of 30 cycles. A PCR thermocycler (Perkin-Elmer, Foster City, California) was
used for the procedure. The presence of the expected 415 bp DNA fragment was















Table 3-1 :The nucleotide sequences of primers used for peR of the HA gene and DNA vaccine construct
are detailed here.
3.1.3 Transfection:
MDCK cells (ATCC, Rockville, MD) were used for transfection and in-vitro
protein expression. Dulbecco's modified Eagle's medium (DMEM) containing
ampicillin, streptomycin and amphotericin (Cellgro, Herndon, Virginia) were used for
cell culture. Standard tissue culture methods as described by George V.G. et al. (George
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V.G, 1996) were foiiowed with modifications. Cells were incubated at 5% CO2 tension in
a CO2 incubator (Revco, Asheville, NC).
3.1.3.1 Transfection by iipofectin:
Seventy to eighty percent confluent MDCK ceiis were harvested using trypsin
EDTA. Cells were resuspended to 2 - 5 X 105 cells/m!. The suspension was used to seed a
six-well tissue culture plate (Becton Dickinson, Lincoln Park, New Jersey). The plate was
incubated overnight in the CO2 incubator at 5% CO2 tension.
Three tubes, each containing 200.0 ul serum-free DMEM. Each tube was added
either 2.0 ug of pHAl , pHA2, or pGFP DNA. Twenty-four micro liters of Lipofectin (1.0
mg/ml solution) (Gibco BRL, Grand Island, New Yark) was added to 600.0 ul of serum
free DMEM in a separate tube, and 200.0 ul of this solution was added to each of the
above DNA-DMEM mixtures. The DNA-liposome mixtures were incubated at room
temperature for 30 min for the fornlation of DNA-liposome complexes. The solutions
were layered onto a monolayer of MDCK cells in a 35 mm petri dish. Six hundred micro
liters of serum-free medium was added to all the wells to a final volume of 1.0 m!. The
plate was incubated for 5 hours in the CO2 incubator, followed by an additional 1.0 ml
DMEM containing 10% FBS. The plates were further incubated overnight.
After 24 hours, cell sheets from the wells were scraped off using a pre-sterilized
rubber policeman. Cells were washed three times in PBS, and lysed by re-suspending in
hypotonic saline solution for 10 minutes. The cells were centrifuged at 1000g for 1.0
minute. The supernatant was collected as the cytosol fraction. The pellet was resuspended
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in sterile distilled and deionized water (ddH20), and centrifuged at 1000g for 1.0 minute.
The supernatant was collected as the nuclear fraction.
PCR reactions were perfonned on both nuclear and cytosolic fractions to verify
the presence of the DNA as a measure of transfection efficiency. Forward primer EH3-
29+ and reverse primer EH3-1 061- were used. The presence of 1.0 Kb DNA fragment in
the nuclear and cytosol fractions indicates the presence of pHA1 or pHA2 into the
transfected cells. Cells transfected with pGFP were used as negative control.
3.1.3.2 Transfection by electroporation:
Transfection of cells was carried out as per the procedure of Chu et al with
modifications (Chu, Hayakawa, and Berg, 1987). Seventy to eighty percent confluent
cells were harvested by washing the cell sheet with PBS, and incubating at 37° C for ten
minutes after addition of 0.5 ml of Trypsin EDTA. The cells were collected into a sterile
, 5ml tube and washed with PBS three times by centrifugation at 500g for 1.0 minute.
They were re-suspended to 2 -5 X 10 6 cells Iml in DMEM without serum. The
suspension was distributed in 400.0 ul volumes in three eppendorf tubes. 20.0 ul of 0.5
uglul of purified plasmid DNA, from clones designated as pHAl and pHA2, were added
to the tubes and allowed to stand for 10 minutes at room temperature for mixing. The
mixture was then loaded into 4.0 mm disposable electroporation cuvettes (BTX) and
pulsed in an electroporator (BTX - ECM 39, Genetronics) at 260 V, 1050 uF, and for 29
microseconds. The cells were incubated in the CO2 incubator for 36 hours. Untransfected
MDCK cells were used as a negative control.
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3.1.4: Western Blot hybridization:
3.1.4.1 Preparation of total celllysates of transfected mammalian MDCK cells:
Transfected cell monolayers in tissue culture flasks were washed three times with
PBS, followed by scrapping with a rubber policeman. The cells were collected into
Eppendorf tubes. They were washed with 500.0 ul of PBS twice, and re-suspended in
50.0 ul of Cell lytic B buffer (Sigma, St. Louis, MO), followed by incubation at room
temperature for five minutes. The cell lysates were centrifuged at 1000 g for 5 minutes.
The supernatant was distributed in 25ul volumes in Eppendorf tubes, and preserved at -
80°C.
3.1.4.2 Polyacrylamide gel electrophoresis:
The procedure of Laemaeli et al (Laemmli, 1970) was followed with modifications.
A 12% gel was cast using the miniprotean II (Biorad, Hercules, California)
- electrophoresis module. Samples were prepared by adding 25.0 ul of 2X sample buffer to
25.0 ul of sample, and boiling at 100 0 C for 5 minutes. Thirty microliter of sample was
added to each well. Medium range molecular weight markers (Sigma, St. Louis, MO)
were added to well 1 and 2, followed by adding purified equine-2 influenza virus,
AlEq/KY/98, as a positive control. Another negative control was provided by
untransfected MOCK cell lysate. The gel was run at 150 V for 45 minutes, using 1X
running buffer (Biorad, Hercules, California) and a power pack (Biorad, Hercules,
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California). Lane I was excised and stained with Coomasie blue and de-stained overnight
to verify proper protein separation on the gel.
3.1.4.3 Protein transfer to nitrocellulose membrane:
Western blot transfer and staining conditions were carried out using the procedure
described by Hartshorn et al. with modifications (Hartshorn et ai., 2000). The SDS-
PAGE gel was equilibrated in transfer buffer for 45 minutes. The nitrocellulose
membrane was cut to the correct dimensions and pre-wetted in transfer buffer, along with
two fiber pads and filter paper cut to size for 45 minutes. The transfer cassette was
arranged by placing the fiber pad, followed by filter paper, gel, nitrocellulose membrane,
filter paper and a fiber pad. The cassette was placed in the Mini Trans-blot apparatus
(Biorad, Hercules, California) following the color code for electrode orientation with
respect to the cassette. Transfer was carried out at room temperature, at 300 rnA and 70
V, for 3.5 hr. The presence of the pre-stained protein markers on the nitrocellulose
membrane confirmed the transfer of protein. The gel was stained with Coomasie blue and
de-stained overnight to verify transfer.
3.1.4.4 Western blot hybridization:
The nitrocellulose membrane was incubated overnight at 4°C in blocking buffer. It
was washed three times for ten minutes in Ix TBS without methanol, and incubated for 2
hours with antibody. A I :3000 dilution of equine convalescent anti-AiEq/KY/98 serum,
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and 1:3000 goat anti-AiEq/Miami/1/63 serum in blocking buffer, was used on two
membranes with transferred cell lysate samples. The membrane was washed again with
TBS, three times and incubated with 1:3000 dilution of secondary antibody in blocking
buffer for 2 hours. Either anti-equine or anti-goat IgG alkaline phosphatase-conjugated
antibodies (Sigma, St. Louis, MO) were used for the respective membrane. The
membrane was then washed three times for ten minutes in washing buffer containing 1.0
% Triton X 100 and 5mM EDTA. One tablet of BCIP/NBT (Sigma, St. Louis, MO)
substrate was dissolved in 10.0 ml of distilled water. The membranes were incubated in
this solution for 30 minutes. The reaction was ended with the stopping buffer. The
membranes were photographed using an image analyzer (Alpha Innotech, San Leandro,
CA)
3.1.5 Mouse challenge study:
3:1.5.1 Experimental design:
This study was adapted with modifications from methods followed by Olsen et al
(Olsen et af., 1997). Groups of four, 20 day-old female BALB/c mice, selected at
random, were separated into the following groups: 1) PBS; 2) inactivated KY/98 virus; 3)
Green Fluorescent Protein; 4) pHA 1 for homologous challenge; 5) pHA 1 for
heterologous challenge; and 6) pHA2. The inactivated virus inoculated group served as
the positive control, both the pGFP group and the PBS group were serving as the negative
control groups. Of the two pHA 1 groups, one group was used for homologous challenge
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with the homologous Virus, NEq/KY/98, while the other group was used for
heterologous challenge, NEq/Prague /56 virus.
Vaccination and serum collection
Booster and serum collection
Serum collection
Serum collection and viral challenge
Body weight measurement (from day
,0 to nav f.))







Fig 3-2: Schedule of the mice challenge experiment.
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TABLE 3-2
MOUSE MODEL TO EVALUATE THE DNA VACCINE
Mice TREATMENT NO. OF DOSE SERUM COLLECTION VIRAL
Group I3ALI3/C & ROUTE (DAYS) CHALLENGE
MICE
PBS 4 20 UL 0,21,35.50 KY/98
(NEGATIVE & DAY 15 POST
CONTROL) CHALLENGE
2 KY 98 4 0.32 HA UNITS/G 0,21,35,50 KY/98




3 PHAI 4 0.01 UG DNA/G 0,21,35,50 KY/98
BODY - WEIGHT & DAY 15 POST
CHALLENGE
4 PHAI 4 0.01 UG DNA/G 0,21,35,50 PRl56
BODY - WEIGHT & DAY 15 POST
CHALLENGE
PHA2 4 0.01 UG DNA/G 0,21,35,50 KY/98
BODY - WEIGHT & DAY 15 POST
CHALLENGE
6 PGFP 4 0.01 UG DNA/G 0,21,35,50 KY/98
(NEGATIVE BODY - WEIGHT & DAY 15 POST
DNA CHALLENGE
CONTROL)
Table 3-2: 6 groups containing 4 mice each were vaccinated with 0.01 ug DNA/g body weight intranasally,
followed by a booster 3 weeks later. Mice were bled on 0, 21, 35, 50 days post inoculation, and 15Th days
posts virus challenge. They were challenged on day 50. The body weight of each mouse was measured each
day for 10 days after challenge with live virus.
40
3.1.5.2 Vaccine formulation:
A 20-ul dose/mouse containing 0.01 ug DNA per gram body weight was
formulated. The dosage contained 20.0 ug of Lipofectamine (GibcoBRL, Grand Island,
New York). Lipofectamine is available as a 1.0-mg/ml solution. Purified plasmid DNA,
pHA1, pHA2 and pGFP were prepared. The purified pHAl DNA contained O.lug/ul,
pHA2 contained 0.05ug/ul and plasmid pGFP contained 0.1 ug/ul as assessed by
visualization on a 1.5% agarose gel. The required quantities of DNA and lipofectamine in
DMEM were mixed and allowed to stand at room temperature for 20 minutes for the
formation of complexes in accordance with the manufacturer instructions.
Twenty micro liters of PBS was administered intranasally to the PBS group. The
KY98 inactivated vaccine group was administered 0.32 HA units/g body weight
intranasally. The inactivated vaccine was prepared from an allantoic fluid culture of
KY/98 virus with a HA titer of 1: 16. The culture was inactivated by placing 1.0 ml of the
virus suspension in a petridish, without lid, at a distance of 15 inches from a 30 W UV
lamp, and irradiated for 15 minutes.
3.1.5.3 Anesthesia of mice:
All bleeding and vaccination procedures were carried out under Isofluorane
(Forane, 1-chloro-2, 2,2-trifluoroethyldifluoromethyl ether) induced anesthesia as per the
method of Wiersema with modifications (Wiersema et al., 1997). A cotton pad soaked
with 0.5 ml of 2% Isofluorane (Abbot labs, North Chicago, IL) was placed in a closed
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glass jar. Mice were held in the jar until loss of pedal and ocular reflexes. An average
time of one and a half minutes was required. Bleeding and vaccination were carried out
when mice were completely anaesthetized.
3.1.5.4 Mice vaccination and bleeding protocol:
Mice were bled on day 0 and vaccinated intra-nasally with the primary dose of
DNA vaccine and inactivated vaccine. They were bled and boosted with the same dose
and by the same route on day 21. They were bled again on day 35 but were not given a
booster vaccination. All groups of mice were bled again on day 50 and were challenged
by intranasal inoculation of SOul an allantoic fluid culture of AlEq/Ky/98 virus with a HA
titer 1: 120 HA units. The heterologous challenge group was challenged with 50 ul of an
allantoic fluid culture of A/Eq/Prague/56 culture with a 1:64 HA titer. Mice body weights
were recorded before challenge and thereafter for 10 days as per the procedure followed
by Solorzano et al (Solorzano et al., 2000). All mice were bled on the 15th day post
challenge and euthanized by Isofluorane® anesthesia, followed by cervical dislocation.
3.1.6 ELISA
Sera samples collected from the mouse challenge experiment were subjected to an
ELISA for assessment of HA specific IgG and IgA antibodies. The method adopted from
Deck et al (Deck et al., 1997) was followed with modifications. 96 well ELISA plates
(Nalge Nunc, Rochester, NY) were coated overnight with 1: 500 dilution of egg allantoic
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fluid harvested KY98 virus In coating buffer at room temperature. The plates were
washed three times with PBS containing 0.05%. Tween-20. They were blocked using
blocking buffer containing 1.5% BSA for 2 hours. The plates were washed three times
again and a 1:10 dilution of the serum in blocking buffer was added in triplicate. Normal
mouse serum was used as a blank and inactivated virus inoculated mouse serum was used
as a positive control. The plates were incubated on a plate shaker at room temperature for
1 hour. The plates were washed three times with washing bufTer and a 1:3000 dilution of
anti mouse IgG and IgA conjugate were added to the respective plates. After an hour's
incubation at room temperature, the plates were washed and 1mg/ml of pNPP (Sigma, St.
Louis, MO) in glycine buffer was added. The plates were read after 150 minutes at 405
nm using the ELISA plate reader (Biotek Instruments, Winooski, VE).
3.1.7 Statistical analysis:
Statistical analysis and graph construction was carried out using Microsoft Excel
software. The standard error of the mean was obtained and represented graphically. A
Student t test was performed on the challenge experiment and ELISA data. Levels of




4.1 Validation of the DNA vaccine construct:
The plasmid DNA construct required to be validated in tenns of: a) The presence
of the HA gene insert; and b) The orientation of the insert with respect to the plasmid
DNA so that the 5' end of the gene is in frame with the CMV promoter.
4.1.1 Restriction digest:
Figs 4-1 and 4-2 are photographs of agarose gels with restriction digestion samples
of plasmids pHA1 and pHA2. The 1.0 Kb band in the sample lanes 3, digested with two




Fig 4-1: Restriction digestion of pHA I: Purified plasmid DNA was subjected to restriction digestion and
electrophoresis in 1.5% agarose gel at 100 V for 30 minutes Lane M I: I Kb DNA ladder; Lane 1:




Fig 4-2: Restriction digestion of pHA2: Purified plasmid DNA was subjected to restriction digestion and
electrophoresis in 1.5% agarose gel at 100 V for 30 minutes. Lane M I: I Kb DNA ladder; Lane I:
Undigested plasmid DNA; Lane 2: DNA digested with EcoR V; Lane 3: DNA digested with EcoR V and
Hind III.
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4.1.1 peR for verification of the orientation of the insert:
Ml 2
Fig 4-3: PCR of pH A1 and pHA2: Purified plasmid DNA pHA I and pHA2 were subjected to PCR using a
forward primer specific to the T7 promoter and a reverse primer specific to an internal site in the HA gene
Lane M I: IKb ladder; Lane I: pHA I; Lane 2: pHA2.
The orientation of the insert in terms of the 5' end of the HA gene being in frame
with the CMV promoter on the plasmid and the 3' end of the gene being in frame with the
tag was verified using PCR. A forward primer was specific to the 5' T7 promoter on the
plasmid backbone and a reverse primer specific to an internal site 415 bps down stream
of the HA gene were used. The expected 415-bp product is evident in lanes 2 &3.
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4.2 Transfection:
MI 2 3 4 5 6 7
Figure 4-4: Transfection: Nuclear and cytosolic fractions from cells transfected with pHA 1, pHA2, and
pGFP were subjected to PCR with EH3-29+ as the forward primer and EH3-1061- as the reverse primer.
Lane Ml: I Kb DNA ladder; Lane I: PCR + control; Lane 2: pGFP cytosol fraction; Lane 3: pGFP nuclear
fraction; Lane 4: pHA I cytosol fraction; Lane 5: pHA2 nuclear fraction; Lane 6: pHA2 cytosol fraction;
Lane7: pHA2 nuclear fraction.
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Cytosol and nuclear fractions from cells transfected with pHAl and pHA2 were
subjected to PCR to ascertain the presence of the plasmids within the cells upon
successful transfection. Forward primer EH3 29 and reverse primer EH3 1061 were
used. Plasmid pGFP was used as a negative DNA control. The expected 1.0 Kb band is
evident in Lanes 4, 5, 6, and 7, which are cytosolic and nuclear fractions of cells
transfected with plasmids pHA 1 and pHA2. The bands are not evident in Lanes 1 and 2
that are pGFP cytosol and nuclear fractions. Lane L shows a 1.0 Kb DNA ladder and lane
C the product of a PCR positive control.
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4.3 Western blot:




Fig 4-5: Western blot with equine anti-KY98 convalescent serum: Total cell lysates of MOCK cells
transfected with plasmids pHA I and pl-lA2 hybridized with equine anti-KY98 convalescent serum. Lane 1:
A/Eq/Ky/98 virus; Lane 2: pl-lA I total cell lysate; Lane 3: pHA2 total cell lysate; Lane 4: Untransfected
MOCK cells; Lane 5: Molecular weight markers
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Fig 4-6: Western blot with goal anti -A/Eq/Miamill/63 serum: Tlolal celllysates ofMDCK cells
transfected with plasm ids pHA I and pHA2 hybridized wilh goat anti-A/Eq/Miami/ll63 antiserum. Lane I:
A/Eq/Ky/98 virus; Lane 2: pHA I [otal cell lysate; Lane 3: pHA2 total cell lysate; Lane 4: Untransfected
MDCK cells; Lane 5: Molecular Weight markers
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To confinn the presence of antigen in vitro, total cell lysates from mammalian
MDCK cells, transfected with plasmids pHA 1 and pHA2, were subjected to Western blot
hybridization. Untransfected MOCK cells were used as the negative control and
A/Eq/KY/98 virus was used as a positive control. Since a 1.0 Kb DNA fragment
encoding the HA 1 segment of the HA gene was cloned, and expressed in mammalian
cells, the product would have a native glycosylation pattern including about 20% of the
molecular weight as carbohydrates (Gray and Tamm, 1998; Sugiura el al., 2001). An
approximately 40 KD band was expected to be present in the lanes with transfected cell
samples (Arora el al., 1985) and absent in the untransfected cell control. Two replicates
of blotted membranes with transferred proteins were probed with two types of antiserum,
convalescent, equine, anti-KY/98 serum and goat anti-A/Eq/Miami/l/63 antiserum. An
approximately 40 KD band is present in the lanes for transfected cells and is absent in the
untransfected control. The presence of several other bands is due to the fact that
polyclonal serum was used.
4.4 Mouse protection study:
4.4.1 Post - challenge body weight loss:
Post-challenge body-weight loss and recovery were taken as the criteria
(Solorzano el al., 2000) to assess the severity of symptoms and protection conferred by
the DNA vaccine. The mean weight loss in treatment groups is compared with that of the






























Figure 4 -78: Post - challenge body weight loss - heterologous challenge.
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Figure 4 - 7E: Post challenge body weight loss - pHA2.
From figures 4-7 A-E, it is evident that the vaccinated mice suffered from less
severe symptoms and recovered more quickly than the unvaccinated mice. The
unvaccinated mice recorded a maximum of 7.9% mean body-weight loss. They did not
recover the initial body-weight for more than 10 days. In comparison, the inactivated
vaccine group lost a maximum of 1.54%, while the pHA1 and pHA2 groups recorded a
maximum loss of 1.8 % and 1.5%, which is comparable to the group immunized with
inactivated virus. The pGFP group lost 4.6% that is less than that that of the control
group. This may be due to the non-specific protection elicited by the DNA vaccine. The
heterologous challenge group recorded a maximum loss of 1.17 % on day 7-post
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challenge. The disease was found to persist for a longer period, although the weight loss
was not as high as that of the unvaccinated group. This can be attributed to the
nonspecific protection elicited by the DNA vaccine (Klinman el al.. 1996). Moreover,
equine-1 influenza virus, A/Eq/Praguell /56, may be less virulent to mice than to equine-2
influenza virus A/Eq/Ky/98.
A Student t test was performed on the data. The body weight loss in the vaccinated
groups showed a statistically significant difference from that unvaccinated group with p
values of P <0.01 while the pGFP group showed a marginal difference with a value of P
value of 0.03.
4.4.2 Post - vaccinate and post - challenge sera anti - HA IgG titers:
Post-immunization sera, collected at 21, 35, 50 day, and sera collected 15 days post-
























Fig 4-8: Elisa titer of HA specific serum IgG - Post vaccinate serum anti HA IgG titers, showing a titer





Fig 4-9: Elisa titer of HA specific serum IgG -15th day post challenge - Sera titers show an anamnestic
response in vaccinated groups and a primary response in unvaccinated groups.
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Post-vaccination and 15 day post virus challenge sera were assayed three times by
ELISA to determine the mean increase in serum anti-HA IgG antibodies. Dilutions of
1:10,1:100, and 1:1000 of the sera were used in the assay. The 1:10 dilution samples
yielded an optimal 0.0. value. The mean value of three replicates was used in data
interpretation and graph construction. The difference in mean values between treatment
group sera and the negative control group sera is depicted in the graphs.
On the 21 day post inoculation, the inactivated vaccine group recorded a mean
a.D. increase of 0.49 (p<O.OI) units above normal mouse sera, while the pHAI and
pHA2 groups recorded an increase of 0.31 (p< 0.01), and 0.28 (p = 0.01) 0.0. units,
respectively. The pGFP group recorded an increase of 0.156 (p = 0.35). The increase in
titers is significant for the inactivated virus and pHA 1 groups.
After administration of a booster dose on day 21, sera from inactivated vaccine
group at 35 day post-inoculation showed an increase of 1.5 (p<O.O 1) 0.0. units. Whereas,
for the pHA group, an increase to 0.55 0.0. units (p<O.OI), and to 0.425 O.D. units
(p<O.OI) for the pHA2 group. No appreciable increase for the pGFP group (p = 0.44).
Day 50 sera remained approximately the same, indicating that the antibody levels were
maintained until this period.
On challenge, vaccinated groups demonstrated an anamnestic increase in serum
IgG titers while the unvaccinated group mounted a primary response. The 0.0. values of
the inactivated vaccine group increased to 1.8 0.0. (p<O.Ol) units over normal mouse
serum and that of the pHAl and pHA2 groups increased by 1.8 (p<O.OI) and 1.7 (p<O.Ol)
O.D. units respectively. The heterologous challenge group recorded an increase of 0.672




tiers of the negative control and pGFP groups increased by 0.81 (p<O.OI) and 0.78 0.0.
units (p<O.O 1) indicating that a primary response was elicited.
4.4.3 Post - vaccinate and post - challenge sera anti - HA IgA titers:
Post-immunization sera, collected at 21, 35, 50 day, and sera collected 15 days post-






















Fig 4-10: Elisa titer of HA specific serum IgA showing an increase in the serum titer of the vaccinated























Fig 4-11: 15th day post challenge sera anti-HA IgA titers showing an anamnestic response in the vaccinated
groups and a primary response in unvaccinated groups.
Post vaccinate and 15th day post-challenge sera samples were assayed three times
by ELISA to detelmine the mean increase in serum anti HA IgA antibodies. Dilutions of
1:10,1:100 and 1:1000 were used in the assay. The 1:10 dilution samples yielded an
optimal a.D. value .The mean value of three replicates was used in data interpretation
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and graph construction. The difference in mean values between treatment group sera and
the negative control group sera is depicted in the graphs.
The 21 SI day sera samples showed a marginal increase in anti- Ha IgA titers when
compared with normal mouse serum. An 0.0. increase of 0.09 (p = 0.01) was recorded
for the inactivated vaccine group, 0.17 for the pHA 1 group (p = 0.01), and 0.19 for the
pHA2 (p = 0.009) group and 0.04 for the pGFP group (p = 0.48).
Upon booster vaccination on day 21,the values increased to 0.265 for the
inactivated vaccine group (p < 0.01),0.36 for the pHAl group (p<O.OI) and 0.38 for the
pHA2 group (p<O.OI). The pGFP group did not record significant increase (p = 0.367).
These antibody levels were maintained at statistically significant levels until day 50. This
demonstrated that intranasal DNA vaccination elicited antigen specific IgA responses,
thus validating the hypothesis that intranasal DNA vaccination will elicit protective IgA
responses.
On challenge, vaccinated groups demonstrated an anamnestic increase in serum
IgA titers while the unvaccinated group mounted a primary response. The 0.0. values for
the inactivated vaccine group increased to 0.74 O.D. (p < 0.01) units over that of normal
mouse serum, while that of the pHAl group increased by 0.48 (p < 0.01) and the pHA2
group by 0.57 (p <0.01). An O.D. increase of 0.34 (p<O.O 1) was recorded for the
unvaccinated group and an increase of 0.19 0.0. (p=0.987) units was recorded for the
pGFP group. An O.D. increase of 0.37(p= 0.749) was recorded for the heterologous




Effective control of influenza is hampered by several factors like the antigenic
shift of the virus and unavailability of effective vaccines. DNA vaccines are a new means
of preventing infectious diseases. They have the advantage of being safer than live
vaccines and eliciting cell mediated responses like live vaccines. This study is an attempt
to evaluate the effectiveness of a DNA vaccine for influenza in eliciting mucosal
immunity. The types of immune responses elicited and protection levels afforded by such
vaccination were also studied.
5.1 Conclusions:
This study provides evidence that a plasmid encoding the immunogenic influenza
HAl gene, after transfection into mammalian cells, transcribes and translates the
recombinant gene, in this case, the HA I viral protein. Furthermore, intranasal
immunization using this DNA vaccine elicits specific IgG and IgA antibodies to the viral
protein.
In contrast to other studies--where the entire HA gene sequence, including the HAl
and HA2 segments were incorporated in the DNA vaccine-- this study included only
HAl gene. It is evident that HA I is sufficient to elicit protective immunity against
homologous challenge.
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It was found that the intranasal route of delivery of DNA using a liposome vehicle
was a very convenient means of administering the vaccine. Dose levels as low as 0.01 ug
DNA/gram body-weight is sufficient to elicit protective immunity against sub-lethal
challenge in mice when administered by this route. Further, the type of immunity elicited
included both IgA and IgG responses. Most other studies involving inoculation by the
intramuscular route were has not been very effective in eliciting mucosal immunity
(Davis, 2001). Gene-gun vaccination, which is also effective, is impractical under field
conditions.
5.2 Significance:
This study provides evidence that DNA vaccination IS an ideal means of
overcoming the disadvantages associated with currently available inactivated influenza
vaccines. It can be expected that this vaccine will prove to be effective in equines. This
model can be extended to human influenza vaccines. Difficulties caused by tedious
procedures involved in viral adaptation to cell and egg culture, vaccine testing and safety
concerns in incorporation of new candidate vaccine strains are eliminated with this type
of vaccination. Extraction of the HA gene from the candidate viral strain and
incorporation in the DNA vaccine is not a time consuming process.
DNA vaccines can be effective in several respiratory infections. Mucosal immune
responses can be elicited by intranasal vaccination. In diseases where a Thl or Th2
response is preferred, the desired kind of immune response can be targeted by altering the
mode of delivery or by incorporation of cytokine encoding genes. This approach is also
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useful in the treatment of allergies where a Th2 response should be suppressed to reduce
19E secretion. DNA vaccination will be particularly useful for diseases such as malaria,
tuberculosis, and HIV. These diseases are caused by intracellular parasites. Conventional
vaccines have not been very effective against these diseases, as they elicit only the
humoral immunity. Antibodies do not neutralize intracellular pathogens, as they are
inaccessible to the specific antibodies. Another advantage for DNA vaccine is that multi-
gene vaccines can be engineered by incorporating immunogenic genes from several
pathogens. The number of vaccinations given to an individual or animal will be reduced.
This will have a beneficial effect on immunization costs, which is not insignificant for
developing countries.
Therefore, DNA vaCCll1es have a vast potential in prevention and treatment of
respiratory infections, infections caused by intracellular parasites, allergies, and cancers.
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